Tony Hunter, Brian Druker and John Mendelsohn have won this year’s Tang Prize in biopharmaceutical science for their breakthroughs in developing targeted cancer therapies, the Tang Prize Selection Committee announced yesterday.
Their research and findings of protein tyrosine phosphorylation and tyrosine kinases as oncogenes have led to successful targeted cancer therapies, the committee said.
The three winners, all Americans, have shown how basic science can lead to clinical applications that benefit humankind, said Chang Wen-chang (張文昌), a member of Academia Sinica and the convener of the selection committee.
Hunter demonstrated that a mechanism called tyrosine phosphorylation acts as a master on/off switch for a number of key proteins that are critical for successful cancer therapies, the committee said.
Hunter, a professor of biology at the Salk Institute, gave birth to the field of targeted therapies after discovering in 1979 the mechanism of tyrosine phosphorylation and that the oncogene Src is a tyrosine kinase.
The historic discovery paved the way for active research in the following two decades on tyrosine kinase oncogenes, ultimately leading to the development of tyrosine kinase inhibitors (TKIs).
Based on Hunter’s discovery, Druker, the director of Oregon Health & Science University’s Knight Cancer Institute, led the successful clinical trial of a cancer-fighting drug called imatinib.
The drug turned chronic myelogenous leukemia, a cancer that once had a very low survival rate, into a manageable condition.
Gleevec, a brand of imatinib, shuts off oncogenic signals by inhibiting Abl-protein tyrosine kinases as predicted by Hunter’s original research, the committee said.
Gleevec has also been successfully used in the treatment of acute lymphocytic leukemia and certain types of gastrointestinal stromal tumors by inhibiting other tyrosine kinase oncoproteins.
There are more than 26 TKIs that have been approved for clinical use. All of the discoveries have Druker’s first successful trials to thank because they spurred this still burgeoning targeted therapy era, the committee said.
John Mendelsohn, president emeritus of MD Anderson Cancer Center, took another approach to combating cancer.
An alternative way of shutting off the activities of tyrosine kinases on the cell surface (receptor tyrosine kinase) is to develop antibodies against the extracellular domain of the receptor, the committee said.
In such a way, the natural ligand, or growth factor, can no longer bind and the receptor tyrosine kinase is no longer activated. Mendelsohn and his team came up with the idea that antibodies targeting the epidermal growth factor receptor (EGFR) may be an effective strategy for cancer treatment.
Mendelsohn led his team in conducting preclinical research and proceeded to develop the anti-EGFR antibody cetuximab, which eventually won the US Food and Drug Administration’s approval for the treatment of colon cancer and head/neck cancer.
SAFETY IN REGULATION: The proposal states that Chiayi should assess whether it is viable to establish such a district and draft rules to protect clients and sex workers The Chiayi City Council passed a motion yesterday to assess the viability of establishing a regulated red-light district. The council yesterday held its last session of the year, at which its fiscal 2024 budget was approved, along with 61 other proposals. The proposal to assess the viability of establishing a red-light district was put forward by independent Chiayi City Councilor Molly Yen (顏色不分藍綠支持性專區顏色田慎節). The proposal cited 2011 amendments to the Social Order Maintenance Act (社會秩序維護法), which stipulate that city and county governments can pass autonomous regulations on the sex trade to manage the industry and guarantee industry workers’ rights. A ban on the
STABILITY AND CHANGE: Flagging in recent polls, Ko this week pledged to maintain President Tsai’s foreign policy, with an emphasis on improving China relations Taiwan People’s Party (TPP) Chairman and presidential candidate Ko Wen-je (柯文哲) yesterday reiterated that he is “deep-green at heart” in response to accusations that he is pivoting his campaign to align closer with the ideology of the Democratic Progressive Party (DPP) in the face of flagging polls. Ko made the remark at an agricultural policy conference in Taipei, repeating his comments from an interview with CTS News a day earlier. Ko told the CTS host that he would continue to pursue President Tsai Ing-wen’s (蔡英文) national defense and foreign policy in general, but with an emphasis on establishing a rapport with
CHINA illness surge: Of 88 travelers from China, Hong Kong and Macau with respiratory symptoms who were encouraged to get tested upon arrival, 70.6% had the flu Two hundred and sixty people with COVID-19 were hospitalized and 31 deaths related to the virus were reported last week — the highest numbers in four weeks, the Centers for Disease Control (CDC) said yesterday, adding that cases are expected to peak next month. CDC Epidemic Intelligence Center Director Guo Hung-wei (郭宏偉) said that of the 260 people hospitalized last week with moderate to severe COVID-19, 98 percent had not received the Omicron XBB.1.5-adapted COVID-19 vaccine. Among the people hospitalized this year, 78 percent were aged 65 or older, while most of the those who were hospitalized or died have or had
Taiwanese who have recently traveled to China for tourism, to visit friends or relatives or for business reasons have been interrogated, detained and faced other forms of unreasonable treatment from Chinese officials, a source said on Sunday. Among them was a Taiwanese who was detained for eight hours at an airport in China due to their research, which is related to religion, while others have had their travel documents for China canceled for a number of reasons, the source said. In July, China expanded the scope of its counterespionage law, and recently announced a draft amendment to the law on the protection